Research & Development

Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded facility.

The new nanomedicines facility includes ‘state-of-the-art GMP-compliant cleanrooms to support Ardena’s growing nanomedicines business, as well as laboratories for process development and analytical work, GMP production space, and warehouse facilities’, according to the company’s press release.

Harry Christiaens, chief executive officer of Ardena, commented: “There is a growing demand for expert nanomedicine services. The €20m expansion of our advanced nanomedicines facility represents a significant investment for Ardena and underscores our commitment to innovation and excellence in pharmaceutical development. With this expanded capacity, we are well equipped to advance nanomedicine research and development, accelerate the development and manufacturing of groundbreaking nanomedicine drugs, bring novel therapies from concept to clinic in a timely and efficient manner, and, ultimately, benefit patients worldwide. […] These developments align seamlessly with Ardena’s mission of expertly guiding clients through every stage of drug development with expertise and precision.”

The new facility spans 2,200m 2 and is located near the company’s existing 4,000m 2 facilities at Pivot Park, Oss, the Netherlands.